CN1121860C - 提高生物利用度的抗真菌组合物 - Google Patents
提高生物利用度的抗真菌组合物 Download PDFInfo
- Publication number
- CN1121860C CN1121860C CN97196513A CN97196513A CN1121860C CN 1121860 C CN1121860 C CN 1121860C CN 97196513 A CN97196513 A CN 97196513A CN 97196513 A CN97196513 A CN 97196513A CN 1121860 C CN1121860 C CN 1121860C
- Authority
- CN
- China
- Prior art keywords
- weight
- pharmaceutical composition
- compositions
- surface active
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000012871 anti-fungal composition Substances 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 60
- 230000000843 anti-fungal effect Effects 0.000 claims abstract description 56
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 55
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- 239000003085 diluting agent Substances 0.000 claims abstract description 10
- 239000004094 surface-active agent Substances 0.000 claims description 37
- 239000002775 capsule Substances 0.000 claims description 33
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 23
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 23
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 23
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 23
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 19
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 19
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 17
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 13
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 13
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 13
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 13
- 238000004132 cross linking Methods 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 10
- 239000000314 lubricant Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 7
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 239000001294 propane Substances 0.000 claims description 7
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 7
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 6
- 229920001400 block copolymer Polymers 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 6
- 239000003429 antifungal agent Substances 0.000 abstract description 4
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 abstract description 3
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 239000008187 granular material Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- -1 polyoxyethylene Polymers 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 229920001993 poloxamer 188 Polymers 0.000 description 7
- 241001597008 Nomeidae Species 0.000 description 6
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 239000007900 aqueous suspension Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000007963 capsule composition Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229960003511 macrogol Drugs 0.000 description 3
- 229950007687 macrogol ester Drugs 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 229940041672 oral gel Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001992 poloxamer 407 Polymers 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920002884 Laureth 4 Polymers 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920002023 Pluronic® F 87 Polymers 0.000 description 2
- 229920001363 Polidocanol Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical group CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
- 229960000201 isosorbide dinitrate Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical group CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Chemical group 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920000034 Plastomer Polymers 0.000 description 1
- 229920002511 Poloxamer 237 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 229920002651 Polysorbate 85 Polymers 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical group O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940061515 laureth-4 Drugs 0.000 description 1
- 229940062711 laureth-9 Drugs 0.000 description 1
- 229950006462 lauromacrogol 400 Drugs 0.000 description 1
- 229940053336 lauromacrogols Drugs 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical group CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940113171 polysorbate 85 Drugs 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
含有下列物质的药用组合物：i)为(-)-(2R-顺式)-4-[4-[4-[4-[[5-(2，4-二氟代苯基)-四氢-5-(1H-1，2，4-三唑-1-基甲基)呋喃-3-基]甲氧基]苯基]-1-哌嗪基]苯基]-2，4-二氢-2-(S)-1-乙基-2-(S)-羟丙基]-3H-1，2，4-三唑-3-酮的抗真菌剂；ii)至少一种非-离子表面活性剂；和iii)稀释剂。该组合物使具有极低水溶性的抗真菌化合物在哺乳动物如人类中具有提高的生物利用度。
Description
技术领域
本发明涉及新的三唑抗真菌化合物的提高或改善了生物利用度的组合物。
背景技术
国际专利申请WO 95/17407号(1995年6月29日公开)介绍了一类新的四氢呋喃/三唑抗真菌化合物。发现其中的一个特殊的化合物(2R-顺式)-4-[4-[4-[4-[[5-(2，4-二氟代苯基)-四氢-5-(1H-1，2，4-三唑-1-基甲基)呋喃-3-基]甲氧基]苯基]-1-哌嗪基]苯基]-2，4-二氢-2-(S)-1-乙基-2-[(S)-羟丙基]-3H-1，2，4-三唑-3-酮在含水混悬剂中对偶发性的真菌例如曲霉属(Aspergillis)、假丝酵母属(Candida)、隐球酵母属(Cryptococcus)以及其它的偶发性真菌具有有效的抗真菌活性。然而，发现非水溶液组合物例如粉剂或颗粒剂的抗真菌活性和/或生物利用度降低，设想是由于该化合物极低的水溶性。因此需要提供抗真菌和/或生物利用度提高或改善的该抗真菌化合物的药用组合物。
发明内容
本发明涉及含有下列物质的药用组合物：
i)下式的抗真菌剂：
ii)至少一种非-离子表面活性剂；和
iii)稀释剂。
所述药用组合物也可以含有其它任选的本领域技术人员已知的赋形剂，例如iv)崩解剂，v)粘合剂，vi)润滑剂，助流剂(glident)和/或着色剂。该药用组合物也可以制成其它适当的剂型，例如胶囊剂(为固体填充的、半固体填充的或液体填充的)、片剂、复制粉剂或口服凝胶。
在另一个实施方案中，本发明涉及包含下列物质的药用组合物：
约18-50％(重量)的抗真菌剂；
约9-50％(重量)的至少一种非离子表面活性剂；
约12-60％(重量)的为微晶纤维素的稀释剂；
约4-10％(重量)的为交联羧甲基纤维素钠的崩解剂；
约3-6％(重量)的为聚乙烯吡咯烷酮的粘合剂；和
约0.3-1.5％(重量)的为硬脂酸镁的润滑剂；和
任选约3-8％(重量)的十二烷基硫酸钠。
我们令人吃惊和出乎意料地发现：在含有特别是抗真菌化合物的药用组合物中包含非离子表面活性剂，可以提高抗真菌化合物的生物利用度(否则具有极低的水溶性)。
也已经发现与水混悬剂相比，在含有特别是抗真菌化合物的药用组合物中包含非离子表面活性剂，可以提高抗真菌化合物的生物利用度。这些结果大大令人吃惊和出乎意料，因为已知的参考资料例如Peter G.Welling(Pharmacokinetics，Processes and Mathematics，AmericanChemical Society，Washington DC，ACS Monograph 185，1986，第57页)指出溶液和混悬剂产生的生物利用度一般比胶囊或片剂更令人满意。J.G.Nairn(Remington’s Pharmaceutical Sciences，第18版，1990，Mack Publishing Co.，第83章，第1519页)也指出因为药物是在溶解状态下被吸收，所以一般发现口服剂型的吸收率按下列顺序降低：水溶液＞水混悬剂＞胶囊或片剂。
本发明具有能够提供抗真菌化合物的药用组合物的优点，该组合物可以容易地制成具有有效抗真菌活性和/或生物利用度的非水溶液或“干燥”剂型，例如胶囊剂、片剂或粉剂。
WO 95/17407(1995年6月29日公开)公开了具有下式的抗真菌化合物和其酯以及醚或其药学上可接受的盐：
其中R1为被一个或两个羟基取代的直链或支链(C3-C8)烷基。在WO95/17407的实施例24和32中指出的上述类别的化合物中特别优选的化合物为抗真菌化合物：(-)-(2R-顺式)-4-[4-[4-[4-[[5-(2，4-二氟代苯基)-四氢-5-(1H-1，2，4-三唑-1-基甲基)呋喃-3-基]甲氧基]苯基]-1-哌嗪基]苯基]-2，4-二氢-2-[(S)-1-乙基-2-(S)-羟丙基]-3H-1，2，4-三唑-3-酮(此后指抗真菌化合物)；式：C37H42F2N8O4；分子量：700.8；m.p.164-165℃，[a]D 25-29℃±3(c＝1.0，CHCl3)，其结构用下式表示：
在抗真菌化合物生产的最后步骤或在常规的结晶步骤后，用常规的微粒化技术可以获得抗真菌化合物微粒化的颗粒。
在使用微粒化技术时，用常规的技术可以将抗真菌化合物微粒化至所需的粒度范围，例如使用球磨机、超声方法或优选使用流能磨碎机如trost流能磨(得自Plastomer Products，Newton，Pennsylvania18940)。当使用流能磨碎机时，所需的粒度可以通过改变向所述磨中加入抗真菌药的送料的速率获得。
约99％微粒化的抗真菌颗粒长度小于或等于100微米，其95％小于或等于90微米。优选约99％微粒化的颗粒长度小于或等于50微米，其95％小于或等于40微米。更优选约99％微粒化的颗粒长度小于或等于20微米，其95％小于或等于10微米。
所述组合物中该抗真菌化合物的用量为有效控制目的真菌。此量可以为该组合物重量的约2％-约85％，更优选5％-约80％，最优选约18％-约50％(重量)。在特定的剂型例如胶囊、片剂等中组合物的量可以为每一剂型含有约10-约500mg抗真菌化合物，优选约50-约200mg。例如在胶囊中可以含有约50或约100mg抗真菌剂。同样，在片剂中可以含有约50mg、约100mg或约200mg抗真菌化合物。
本发明的药用组合物可以制成任何适当的剂型，例如胶囊(为固体填充的、半固体填充的或液体填充的)、片剂、复制粉剂或口服凝胶。
用下列术语描述本发明的药用组合物、可以用于其制剂的成分以及评价其生物活性或生物利用度的方法。
剂型-指制成释放体系的含有抗真菌化合物以及无活性的成分的组合物，即片剂、胶囊剂、口服凝胶、复制粉剂或混悬剂。
胶囊-指由甲基纤维素、聚乙烯醇或变性明胶或淀粉制得的用于保存或容纳含有所述活性抗真菌化合物的组合物的特定的容器或外壳。硬壳胶囊一般由相对高胶凝强度的骨明胶和猪皮明胶的混合物制得。所述胶囊本身可以含有少量的染料、遮光剂、增塑剂和防腐剂。
片剂-指含有活性成分(抗真菌化合物)以及适当的稀释剂的压制或模塑的固体剂型。可以通过压制混合物或经湿法制粒、干法制粒或挤压获得的颗粒制备所述片剂。
口服胶凝剂-指分散或溶解于亲水半固体基质中的抗真菌药物。
复制粉剂指含有抗真菌药物和适当的稀释剂的粉末混合物，可以将其悬浮于水或糖浆中。
表面活性剂-指可以减少两个不相混溶的相间的界面张力的化合物，因为表面活性剂是含有两个局部的分子，一部分为亲水性的，另一部分为亲油性的。
非离子表面活性剂-指缺少静离子电荷并在含水介质中不会离解至明显程度的表面活性剂。非离子表面活性剂的性质主要取决于分子中亲水性和亲油性基团的比例。亲水性基团包括氧化乙烯基(-OCH2CH2-)和羟基。通过改变亲油性分子如脂肪酸中上述基团的数目，可获得从强亲油性和水不溶性化合物如单硬脂酸甘油酯到强亲水性和水溶性化合物如macrogol的物质。在这两种极端类型之间包括那些亲水性和亲油性基团的比例较均匀平衡的物质，如macrogol酯和醚以及脱水山梨醇衍生物。适当的非离子表面活性剂可发现于Martindale的The Extra Pharmacopoeia(第28版，1982，The Pharmaceutical Press，London，Great Britan，第370-379页)。这些非离子表面活性剂包括环氧乙烷和氧化丙烷的嵌段共聚物、脂肪酸的乙二醇和甘油酯及其衍生物、脂肪酸的聚氧乙烯酯(macrogol酯)、脂肪酸的聚氧乙烯醚及其衍生物(macrogol醚)、聚乙烯醇和脱水山梨醇酯。
优选的非离子表面活性剂为环氧乙烷和环氧丙烷的嵌段共聚物。
适当的环氧乙烷和环氧丙烷的嵌段共聚物一般称为“Poloxamers”，它包括下面化学结构所表示的那些物质：
其中a为从约10-约110的整数，优选约12-101，更优选约12-80；和
b为约20-约60的整数，更优选约20-约56；也优选约20-27。更优选，a为80，b为27，或者称为PluronicF68表面活性剂，BASFCorporation的商标名，Mount Olive，New Jersey，USA。PluronicF68表面活性剂也称为Poloxamer 188。该表面活性剂的平均分子量为8400，在20℃时为固体，77℃时粘度(Brookfield)为1000cps。其它适当的环氧乙烷和环氧丙烷的嵌段共聚物包括Pluronic F87，也称为Poloxamer 237，其中a为64，b为37；和Pluronic F127，也称为Poloxamer 407，其中a为101，b为56。
适当的脂肪酸的乙二醇酯和甘油酯以及它们的衍生物包括单油酸甘油酯和相似的水溶性衍生物。
适当的脂肪酸的聚氧乙烯酯(macrogol酯)包括聚氧乙烯蓖麻油和氢化蓖麻油衍生物；
适当的脂肪酸聚氧乙烯醚和它们的衍生物(macrogol醚)包括Cetomacrogel 1000、Lauromacrogols(一系列不同链长的macrogols的十二烷基醚)如Laureth 4、Laureth 9和Lauromacrogol 400。
适当的脱水山梨醇酯(脱水山梨醇中的一个或多个羟基与脂肪酸例如硬脂酸、棕榈酸、油酸或月桂酸形成的酯)包括，如Polysorbate 20、Polysorbate 40、Polysorbate 60、Polysorbate 65、Polysorbate 80、Polysorbate 85、脱水山梨醇单月桂酸酯、脱水山梨醇单油酸酯、脱水山梨醇单棕榈酸酯、脱水山梨醇单硬脂酸酯、脱水山梨醇倍半油酸酯、脱水山梨醇三油酸酯和脱水山梨醇三硬脂酸酯。
所述组合物中非离子表面活性剂的量为总组合物的约5-约50％(重量)，更优选为约5-约25％(重量)。
本发明的组合物也可任选含有阴离子表面活性剂，如十二烷基硫酸钠，其用量为总组合物的约1-约10％(重量)，更优选约3-约8％(重量)。
稀释剂-指通常用于补充所述组合物或剂型的主要部分的物质。适当的稀释剂包括糖，如乳糖、蔗糖、甘露醇或山梨醇；来自小麦、玉米和马铃薯的淀粉；纤维素如微晶纤维素。所述组合物中稀释剂的用量可为总组合物的约10-约90％(重量)，优选约25-约75％，更优选约30-约60％(重量)，甚至更优选约12-约60％。
崩解剂-指加入到所述组合物中以帮助其分解(崩解)和释放药物的物质。适当的崩解剂包括淀粉；“冷水可溶性”改良淀粉，例如羧甲基淀粉钠；天然和合成树胶，例如刺槐豆胶、刺梧桐树胶、瓜耳胶、黄蓍胶和琼脂；纤维素衍生物例如甲基纤维素和羧甲基纤维素钠；微晶纤维素和交联微晶纤维素例如交联羧甲基纤维素钠；藻酸盐例如藻酸和藻酸钠；粘土例如膨润土以及泡腾剂混合物。所述组合物中崩解剂的量可以为组合物的约2-约15％(重量)，更优选约4-约10％(重量)。
粘合剂-指将粉末粘合或“胶粘”在一起的物质并通过形成颗粒使它们粘结，因此在所述制剂中用作“粘结剂”。粘合剂可以增加所述稀释剂或填充剂的粘结力。适当的粘合剂包括糖，例如蔗糖；来自小麦、玉米和马铃薯的淀粉；天然树胶例如阿拉伯胶、明胶和黄蓍胶；海藻衍生物例如藻酸、藻酸钠和藻酸铵钙；纤维性物质例如甲基纤维素和羧甲基纤维素钠和羟丙基甲基纤维素；聚乙烯吡咯烷酮以及无机物例如硅酸镁铝。组合物中粘合剂的量可以为组合物的约2-约20％(重量)，更优选约3-约10％(重量)，甚至更优选约3-约6％(重量)。
润滑剂-指加入到剂型中以使片剂、颗粒剂等在压制后通过降低磨擦或磨损从塑模或冲模中脱模的物质。适当的润滑剂包括金属硬脂酸盐，例如硬脂酸镁、硬脂酸钙或硬脂酸钾；硬脂酸；高熔点蜡；和水溶性润滑剂例如氯化钠、苯甲酸钠、乙酸钠、油酸钠、聚乙二醇和d，1-亮氨酸。通常在压制前最后一个步骤加入润滑剂，因为它们必须存在于所述颗粒的表面上和存在于颗粒与压片机部件之间。所述组合物中润滑剂的量可以为组合物的约0.2-约5％(重量)，优选为0.5-约2％，更优选为约0.3-约1.5％(重量)。
助流剂-指预防结块并提高颗粒流动性的物质，以使流动平滑且均匀。适当的助流剂包括二氧化硅和滑石粉。组合物中助流剂的量可以为总组合物的约0.1-约5％(重量)，优选为0.5-约2％(重量)。
着色剂-指给所述组合物或所述剂型提供颜色的赋形剂。此类赋形剂可包括吸附在适当的吸附剂例如粘土或氧化铝上的食物级别的染料和食物级别颜料。着色剂的量为组合物的约0.1-约5％(重量)，优选约0.1-约1％。
生物利用度-指与标准或对照相比，所述活性药物成分或治疗部分由给药的剂型吸收进入系统循环的速率和程度。
Cmax值指测量的抗真菌化合物的最大血浆浓度(即“峰值”)。
AUC(0-72hr)值指在指定时间内抗真菌剂血浆/血清浓度-时间曲线下的面积。
制备片剂的常规方法是已知的。此类方法包括干法，例如直接压片和由挤压生产的颗粒压片或湿法或其它特定的方法。
可以通过将抗真菌化合物与含有表面活性剂以及所需量的稀释剂和任选的崩解剂、润滑剂、粘合剂、助流剂和/或着色剂的非离子聚环氧乙烷和环氧丙烷混合或制粒制备本发明的组合物。然后可以将上述组合物用于填充胶囊。或者可以将上述组合物压制成片剂。
下列实施例描述含有所述抗真菌化合物的本发明的组合物，但是不认为它们限制权利要求书的范围。
具体实施方式
实施例1.胶囊组合物组分 mg/胶囊 ％wt抗真菌化合物 100 19Pluronic F68表面活性剂 50 9.5微晶纤维素 300 56.9(a)交联羧甲基纤维素钠 25 4.7聚乙烯吡咯烷酮 25 4.7(b)交联羧甲基纤维素钠 25 4.7硬脂酸镁 2.5 0.5
527.5 100
实施例2.胶囊组合物组分 mg/胶囊 ％wt抗真菌化合物 100 25Pluronic F68表面活性剂 100 25微晶纤维素 136 34(a)交联羧甲基纤维素钠 20 5聚乙烯吡咯烷酮 20 5(b)交联羧甲基纤维素钠 20 5硬脂酸镁 4 1
400 100
实施例1-2、4-5、10-12和15中胶囊的制备
在适当的混合器中，根据实施例10-12的方法，将抗真菌化合物、Pluronic F68、微晶纤维素稀释剂、(a)交联羧甲基纤维素钠崩解剂和任选的十二烷基硫酸钠混合5-10分钟。将聚乙烯吡咯烷酮粘合剂溶于水中，用该聚乙烯吡咯烷酮溶液将上述混合物制粒。将已制粒的混合物置于烘箱中于45-50℃干燥过夜或流化床干燥至水分小于2％。将颗粒过20目筛并混合研磨的颗粒5分钟。取部分研磨的颗粒，与硬脂酸镁润滑剂混合，过筛，然后将该过筛的颗粒与上述研磨的颗粒的剩余部分一起混合。加入(b)交联羧甲基纤维素钠并混合5-10分钟。将颗粒填充进适当大小的胶囊中至所需的装量。
实施例3.在水混悬剂中的组合物
制备在4ml蒸馏水中的含有59.8mg Pluronic F68的混悬剂。向上述溶液中加入200mg抗真菌化合物，混合以得到均匀的混悬剂。
对照实施例.胶囊剂组分 mg/胶囊 ％wt抗真菌化合物 100.0 28.6十二烷基硫酸钠表面活性剂 22.5 6.4微晶纤维素 178.0 50.9羟乙酸淀粉钠 45.0 12.8硬脂酸镁 4.5 1.3
350 100
对照实施例中胶囊的制备
在混合器中将抗真菌化合物、十二烷基硫酸钠(表面活性剂)、微晶纤维素和羟乙酸淀粉钠混合10分钟。加入硬脂酸镁并混合5分钟。将颗粒填充进适当大小的胶囊中至所需的装量。
生物利用度实验
将在二个胶囊中的或在混悬剂中的200mg剂量的抗真菌化合物给狗喂药。于选定的时间收集血清样本并用装备有紫外检测器的高效液相色谱通过HPLC/UV检测程序进行分析。在下表中，Cmax和AUC(0-72hr)值为抗真菌化合物的生物利用度的指标。AUC值越大，血清中超过72小时期间所积累的抗真菌化合物的总量越大。
| 生物利用度指标 | 胶囊实施例1 | 胶囊实施例2 | 混悬剂实施例3 | 胶囊对照实施例 |
| Cmax | 2.3 | 1.8 | 1.5 | 0.95 |
| AUC(0-72hr)μg/hr/ml | 92.5 | 69.4 | 59.3 | 29.72 |
上述结果表明实施例1和2胶囊的生物利用度超过实施例3的水混悬剂的生物利用度，明显超过对照实施例胶囊的生物利用度。
实施例4.胶囊中的组合物组分 mg/胶囊 ％wt抗真菌化合物 50.00 19Pluronic F68表面活性剂 25.00 9.5微晶纤维素 150.00 56.9(a)交联羧甲基纤维素钠 12.50 4.7聚乙烯吡咯烷酮 12.50 4.7(b)交联羧甲基纤维素钠 12.50 4.7硬脂酸镁 1.25 0.5
263.75 100
实施例5.胶囊中的组合物组分 mg/胶囊 ％wt抗真菌化合物 100.00 22.2Pluronic F68表面活性剂 50.00 11.1微晶纤维素 245.25 54.5(a)交联羧甲基纤维素钠 15.00 3.3聚乙烯吡咯烷酮 22.50 5.0(b)交联羧甲基纤维素钠 15.00 3.3硬脂酸镁 2.25 0.5
450.00 100
实施例6.片剂中的组合物组分 mg/片 ％wt抗真菌化合物 100.00 22.2Pluronic F68表面活性剂 50.00 11.1微晶纤维素 245.25 54.5(a)交联羧甲基纤维素钠 15.00 3.3聚乙烯吡咯烷酮 22.50 5.0(b)交联羧甲基纤维素钠 15.00 3.3硬脂酸镁 2.25 0.5
450.00 100
实施例7.片剂中的组合物组分 mg/片 ％wt抗真菌化合物 100.0 19Pluronic F68表面活性剂 50.0 9.5微晶纤维素 300.0 56.9(a)交联羧甲基纤维素钠 25.0 4.7聚乙烯吡咯烷酮 25.0 4.7(b)交联羧甲基纤维素钠 25.0 4.7硬脂酸镁 2.5 0.5
527.5 100
实施例8.片剂中的组合物组分 mg/片 ％wt抗真菌化合物 200.0 19Pluronic F68表面活性剂 100.0 9.5微晶纤维素 600.0 56.9(a)交联羧甲基纤维素钠 50.0 4.7聚乙烯吡咯烷酮 50.0 4.7(b)交联羧甲基纤维素钠 50.0 4.7硬脂酸镁 5.0 0.5
1025.0 100
实施例9.片剂中的组合物组分 mg/片 ％wt抗真菌化合物 200.0 22.2Pluronic F68表面活性剂 100.0 11.1微晶纤维素 490.5 54.5(a)交联羧甲基纤维素钠 30.0 3.3聚乙烯吡咯烷酮 45.0 5.0(b)交联羧甲基纤维素钠 30.0 3.3硬脂酸镁 4.5 0.5
900.0 100
实施例6-9和13-14中片剂的制备
在适当的混合器中，根据实施例13-14的方法，将抗真菌化合物、Pluronic F68、微晶纤维素稀释剂、(a)交联羧甲基纤维素钠崩解剂和任选的十二烷基硫酸钠混合5-10分钟。将聚乙烯吡咯烷酮粘合剂溶于水中，用该聚乙烯吡咯烷酮溶液将上述混合物制粒。将已制粒的混合物置于烘箱中于45-50C干燥过夜或流化床干燥至水分小于2％。将颗粒过20目筛并混合研磨的颗粒5分钟。取部分研磨的颗粒，与硬脂酸镁润滑剂混合，过筛，然后将该过筛的颗粒与上述研磨的颗粒的剩余部分一起混合。加入(b)交联羧甲基纤维素钠并混合5-10分钟。将颗粒压制成所需重量的片剂。
实施例10.胶囊中的组合物组分 mg/胶囊 ％wt抗真菌化合物 200.00 44.44Pluronic F68表面活性剂 100.00 22.23十二烷基硫酸钠 30.00 6.67微晶纤维素 65.26 14.50(a)交联羧甲基纤维素钠 15.00 3.33聚乙烯吡咯烷酮 22.50 5.0(b)交联羧甲基纤维素钠 15.00 3.33硬脂酸镁 2.24 0.5
450.00 100
实施例11.胶囊中的组合物组分 mg/胶囊 ％wt抗真菌化合物 200.00 44.44Pluronic F68表面活性剂 50.00 22.23十二烷基硫酸钠 15.00 6.67微晶纤维素 32.63 14.50(a)交联羧甲基纤维素钠 7.50 3.33聚乙烯吡咯烷酮 11.25 5.0(b)交联羧甲基纤维素钠 7.50 3.33硬脂酸镁 1.12 0.5
225.00 100
实施例12.胶囊中的组合物组分 mg/胶囊 ％wt抗真菌化合物 100.00 26.67Pluronic F68表面活性剂 50.00 13.33十二烷基硫酸钠 15.00 4.00微晶纤维素 164.38 43.84(a)交联羧甲基纤维素钠 12.50 3.33聚乙烯吡咯烷酮 18.75 5.0(b)交联羧甲基纤维素钠 12.50 3.33硬脂酸镁 1.87 0.5
375.00 100
实施例13.片剂中的组合物组分 mg/片 ％wt抗真菌化合物 100.00 22.22Pluronic F68表面活性剂 50.00 11.11十二烷基硫酸钢 30.00 6.67微晶纤维素 215.25 47.84(a)交联羧甲基纤维素钠 15.00 3.33聚乙烯吡咯烷酮 22.50 5.00(b)交联羧甲基纤维素钠 15.00 3.33硬脂酸镁 2.25 0.50
450.0 100
实施例14.片剂中的组合物组分 mg/片 ％wt抗真菌化合物 200.00 22.22Pluronic F68表面活性剂 100.00 11.11十二烷基硫酸钠 30.00 6.67微晶纤维素 430.50 47.84(a)交联羧甲基纤维素钠 30.00 3.33聚乙烯吡咯烷酮 45.00 5.00(b)交联羧甲基纤维素钠 30.00 3.33硬脂酸镁 4.50 0.50
450.00 100
实施例15.胶囊中的组合物组分 mg/胶囊 ％wt抗真菌化合物 100.00 26.67Pluronic F68表面活性剂 50.00 13.33微晶纤维素 179.38 47.84(a)交联羧甲基纤维素钠 12.50 3.33聚乙烯吡咯烷酮 18.75 5.00(b)交联羧甲基纤维素钠 12.50 3.33硬脂酸镁 1.87 0.50
375.00 100
实施例16-23胶囊组合物。用基本与实施例1-2、4-5和10-12相同的方法，但是用Pluronic F87代替Pluronic F68。
实施例24-29片剂组合物。用基本与实施例6-9和13-14相同的方法，但是用Pluronic F127代替Pluronic F68。
Claims (8)
1.一种用于治疗真菌感染的药用组合物，该组合物包含
18-50％重量下式的抗真菌剂：
9-50％重量至少一种非离子表面活性剂，该表面活性剂为环氧乙烷和环氧丙烷的嵌段共聚物；
12-60％重量稀释剂，所述稀释剂为微晶纤维素；
4-10％重量崩解剂，所述崩解剂为交联羧甲基纤维素钠；
3-6％重量粘合剂，所述粘合剂为聚乙烯吡咯烷酮；
0.3-1.5％重量润滑剂，所述润滑剂为硬脂酸镁；
并包含或不包含3-8％重量十二烷基硫酸钠；其中所述组合物为胶囊、片剂或复制粉剂。
2.权利要求1的药用组合物，其中所述非离子表面活性剂为下列化学结构代表的环氧乙烷和环氧丙烷的嵌段共聚物：其中
a为10-110的整数，
b为20-60的整数。
3.权利要求2的药用组合物，其中对于所述非离子表面活性剂而言，
a为12-80的整数，
b为20-56的整数。
4.权利要求2的药用组合物，其中对于所述非离子表面活性剂而言，a为80，b为27。
5.权利要求1-4中任一项的药用组合物，其中所述非离子表面活性剂在组合物中的量为9.5-11％重量。
6.权利要求1-4中任一项的药用组合物，其中所述组合物中的非离子表面活性剂为普流罗尼克F68表面活性剂。
7.权利要求1的药用组合物，其中所述崩解剂的量为5.0％重量。
8.权利要求1的药用组合物，其中所述粘合剂的量为5.0％重量。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65532996A | 1996-05-24 | 1996-05-24 | |
| US08/655,329 | 1996-05-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1228699A CN1228699A (zh) | 1999-09-15 |
| CN1121860C true CN1121860C (zh) | 2003-09-24 |
Family
ID=24628452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97196513A Expired - Fee Related CN1121860C (zh) | 1996-05-24 | 1997-05-21 | 提高生物利用度的抗真菌组合物 |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP0914127B1 (zh) |
| JP (1) | JP3366648B2 (zh) |
| KR (1) | KR100307427B1 (zh) |
| CN (1) | CN1121860C (zh) |
| AR (1) | AR007250A1 (zh) |
| AT (1) | ATE213632T1 (zh) |
| AU (1) | AU719109B2 (zh) |
| BR (1) | BR9711167A (zh) |
| CA (1) | CA2255663C (zh) |
| CO (1) | CO4840511A1 (zh) |
| CZ (1) | CZ293586B6 (zh) |
| DE (1) | DE69710729T2 (zh) |
| ES (1) | ES2169440T3 (zh) |
| HK (1) | HK1017855A1 (zh) |
| HU (1) | HU221371B1 (zh) |
| ID (1) | ID16956A (zh) |
| IL (1) | IL126979A (zh) |
| MY (1) | MY118988A (zh) |
| NO (1) | NO316997B1 (zh) |
| NZ (1) | NZ332699A (zh) |
| PE (1) | PE68898A1 (zh) |
| PL (1) | PL188401B1 (zh) |
| RU (1) | RU2207119C2 (zh) |
| SK (1) | SK281818B6 (zh) |
| TR (1) | TR199802424T2 (zh) |
| TW (1) | TW504390B (zh) |
| WO (1) | WO1998007429A2 (zh) |
| ZA (1) | ZA974428B (zh) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2157731B1 (es) * | 1998-07-21 | 2002-05-01 | Liconsa Liberacion Controlada | Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion. |
| EP1175205B1 (en) | 1999-11-12 | 2006-06-14 | Abbott Laboratories | Solid dispersion comprising ritonavir, fenofibrate or griseofulvin |
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| DK1413331T3 (da) * | 2001-01-26 | 2007-12-10 | Schering Corp | Kombinationer af peroxisomproliferatoraktiveret receptor (PPAR)-aktivatoren fenofibrat og sterolabsorptionsinhibitoren ezetimib til vaskulære indikationer |
| WO2004066981A1 (en) * | 2003-01-29 | 2004-08-12 | Sun Pharmaceutical Industries Limited | Oral controlled release pharmaceutical composition containing metaxalone as active agent |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| SG190117A1 (en) | 2010-11-01 | 2013-06-28 | Rib X Pharmaceuticals Inc | Pharmaceutical compositions |
| RU2450807C1 (ru) * | 2011-05-11 | 2012-05-20 | Общество с ограниченной ответственностью фирма "Вита" | Стабилизированный фармацевтический состав с противогрибковым действием |
| CN103845292A (zh) * | 2012-11-29 | 2014-06-11 | 正大天晴药业集团股份有限公司 | 泊沙康唑微丸及其制备方法 |
| US9763934B2 (en) * | 2014-03-05 | 2017-09-19 | Professional Compounding Centers Of America | Synergistic effect of poloxamer-based composition and itraconazole on fungus and yeast |
| TR201620462A2 (tr) | 2016-12-31 | 2018-07-23 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4791111A (en) * | 1985-12-23 | 1988-12-13 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties |
| US5039676A (en) * | 1990-05-11 | 1991-08-13 | Schering Corporation | Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ294823B6 (cs) * | 1993-12-21 | 2005-03-16 | Schering Corporation | Fungicidní tetrahydrofurany |
-
1997
- 1997-05-21 NZ NZ332699A patent/NZ332699A/xx not_active IP Right Cessation
- 1997-05-21 SK SK1608-98A patent/SK281818B6/sk not_active IP Right Cessation
- 1997-05-21 PE PE1997000400A patent/PE68898A1/es not_active Application Discontinuation
- 1997-05-21 TW TW086106780A patent/TW504390B/zh not_active IP Right Cessation
- 1997-05-21 KR KR1019980709501A patent/KR100307427B1/ko not_active IP Right Cessation
- 1997-05-21 CA CA002255663A patent/CA2255663C/en not_active Expired - Fee Related
- 1997-05-21 BR BR9711167A patent/BR9711167A/pt not_active IP Right Cessation
- 1997-05-21 DE DE69710729T patent/DE69710729T2/de not_active Expired - Lifetime
- 1997-05-21 HU HU9904265A patent/HU221371B1/hu not_active IP Right Cessation
- 1997-05-21 EP EP97949341A patent/EP0914127B1/en not_active Expired - Lifetime
- 1997-05-21 CN CN97196513A patent/CN1121860C/zh not_active Expired - Fee Related
- 1997-05-21 IL IL12697997A patent/IL126979A/xx not_active IP Right Cessation
- 1997-05-21 WO PCT/US1997/019388 patent/WO1998007429A2/en active IP Right Grant
- 1997-05-21 ES ES97949341T patent/ES2169440T3/es not_active Expired - Lifetime
- 1997-05-21 CO CO97027673A patent/CO4840511A1/es unknown
- 1997-05-21 TR TR1998/02424T patent/TR199802424T2/xx unknown
- 1997-05-21 RU RU98123611/14A patent/RU2207119C2/ru not_active IP Right Cessation
- 1997-05-21 AU AU59399/98A patent/AU719109B2/en not_active Ceased
- 1997-05-21 PL PL97330480A patent/PL188401B1/pl not_active IP Right Cessation
- 1997-05-21 ID IDP971708A patent/ID16956A/id unknown
- 1997-05-21 ZA ZA9704428A patent/ZA974428B/xx unknown
- 1997-05-21 CZ CZ19983790A patent/CZ293586B6/cs not_active IP Right Cessation
- 1997-05-21 JP JP50544798A patent/JP3366648B2/ja not_active Expired - Fee Related
- 1997-05-21 AT AT97949341T patent/ATE213632T1/de not_active IP Right Cessation
- 1997-05-22 MY MYPI97002234A patent/MY118988A/en unknown
- 1997-05-22 AR ARP970102173A patent/AR007250A1/es active IP Right Grant
-
1998
- 1998-11-23 NO NO19985447A patent/NO316997B1/no not_active IP Right Cessation
-
1999
- 1999-07-13 HK HK99103016A patent/HK1017855A1/xx not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4791111A (en) * | 1985-12-23 | 1988-12-13 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties |
| US5039676A (en) * | 1990-05-11 | 1991-08-13 | Schering Corporation | Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5834472A (en) | Antifungal composition with enhanced bioavailability | |
| CN1228693A (zh) | 含有三唑类抗真菌化合物的口服组合物 | |
| US5846971A (en) | Oral antifungal composition | |
| CN1025150C (zh) | 能延续释放的新药物制剂的制备方法 | |
| CN1206984C (zh) | 具有外涂一种杀真菌剂和一种聚合物的核心的药丸 | |
| CN1213754C (zh) | β－咔啉药物组合物 | |
| CN1121860C (zh) | 提高生物利用度的抗真菌组合物 | |
| CN1273194C (zh) | 水溶性差的活性物质的口服固溶体配方 | |
| CN1390127A (zh) | 含有伊曲康唑的抗真菌口服组合物及其制备方法 | |
| CN101052381A (zh) | 包含替米沙坦和氨氯地平的双层片剂 | |
| CN1221256C (zh) | 药物组合物 | |
| CN1522140A (zh) | 奥卡西平剂型 | |
| CN101056658A (zh) | 具有改善生物利用度的口服制剂 | |
| CN101057834A (zh) | 含有肠溶固体分散体的固体制剂 | |
| CN1210065C (zh) | 具有改善溶出性能的普仑司特的固体分散体系及其制备方法 | |
| CN1819817A (zh) | 一种泰克利玛的固体分散体 | |
| CN1872048A (zh) | 黄豆苷元滴丸及其制备方法 | |
| CN1203845C (zh) | 含有普鲁芬的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: MSD CORP. Free format text: FORMER NAME: SCHERING CORP (US) |
|
| CP01 | Change in the name or title of a patent holder |
Address after: new jersey Patentee after: Schering Corporation Address before: new jersey Patentee before: SCHERING CORP (US) |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20030924 Termination date: 20140521 |